ESR1 and breast carcinoma: The not yet fully published Unicancer ASTER 70s trial randomized older (≥70 years) estrogen receptor (ER)-positive, HER2-negative, early-stage breast cancer patients with a high genomic grade index (GGI) between CT + ET and ET alone [30].